Published in Women's Health Weekly, January 27th, 2005
Within the program, which was initiated November, 2003, Galapagos has used its osteoporosis disease expertise in combination with its SilenceSelect adenoviral siRNA platform to discover and validate novel drug targets that may affect bone remodeling.
Wyeth has now selected a set of these targets for internal development, triggering a financial milestone for Galapagos. As these targets are progressed by Wyeth, Galapagos has rights to additional...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.